Ligand id: 9864

Name: tregalizumab

Immunopharmacology Comments
Tregalizumab was designed to selectively activate Treg cells and boost their function to mediate an increase in their immunosuppressive activity [1-2].
Immunopharmacology Disease
Disease X-Refs Comment References
Rheumatoid arthritis Disease Ontology: DOID:7148
OMIM: 180300
Tregalizumab failed to show clinical efficacy in Phase 2 trial (NCT01999192), and development was discontinued. 3